Wedbush Reiterated an Outperform on Cerulean Pharma (CERU) Following 3Q

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Wedbush Reiterated an Outperform on Cerulean Pharma (CERU) Following 3Q

Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101

November 17, 2015 7:00 AM EST

Three-Party Collaboration Will Explore Synergies Between AstraZenecas Leading PARP Inhibitor and Ceruleans Topoisomerase Inhibitor

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (Nasdaq: CERU) announced today that it has entered into a collaboration with AstraZeneca AB (AstraZeneca) and the National Cancer Institute (NCI), part of the National Institutes of Health, to... More

Cerulean Reports Third Quarter 2015 Corporate Highlights and Financial Results

November 16, 2015 4:35 PM EST

Conference Call Today at 4:30 p.m.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended September 30, 2015.

During the third quarter, we strengthened our management team by appointing... More